VERSACROSS CONNECT ACCESS SOLUTION FOR FARADRIVE
Report
- Report Number
- 2124215-2026-02475
- Event Type
- Injury
- Date Received
- January 14, 2026
- Date of Event
- December 26, 2025
- Report Date
- February 18, 2026
- Manufacturer
- BAYLIS MEDICALE CIE INC
- Product Code
- DXF
- PMA / PMN Number
- K150709
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- NJ, US
- Reporter Occupation
- PHYSICIAN
- Health Professional
- Yes
Narratives
DUE TO ADDITIONAL INFORMATION RECEIVED, THIS SUPPLEMENTAL REPORT IS BEING SUBMITTED FOR THE UPDATED FIELD DESCRIBE EVENT OR PROBLEM (B5), IN SECTION B - ADVERSE EVENT OR PRODUCT PROBLEM. IT WAS INDICATED THAT THE DEVICE WILL NOT BE RETURNED FOR EVALUATION. IF THERE IS ANY FURTHER RELEVANT INFORMATION OBTAINED, A SUPPLEMENTAL MEDWATCH WILL BE FILED. DETAILED PRODUCT INFORMATION WAS NOT PROVIDED TO BSC. WE COMPLETED A GOOD FAITH EFFORT TO OBTAIN THE INFORMATION, BUT IT WAS NOT AVAILABLE. BECAUSE THE PRODUCT IS UNKNOWN, WE ARE UNABLE TO PROVIDE THE UNIQUE IDENTIFIER (UDI) AND OTHER SPECIFIC PRODUCT INFORMATION.
IT WAS INDICATED THAT THE DEVICE WILL NOT BE RETURNED FOR EVALUATION. IF THERE IS ANY FURTHER RELEVANT INFORMATION OBTAINED, A SUPPLEMENTAL MEDWATCH WILL BE FILED. GOOD FAITH EFFORT ATTEMPTS TO TRY AND RETRIEVE ADDITIONAL DETAILS REGARDING THE REPORTED EVENT ARE IN PROGRESS, BUT FURTHER INFORMATION WAS UNABLE TO BE OBTAINED. IF THERE IS ANY FURTHER RELEVANT INFORMATION OBTAINED, A SUPPLEMENTAL MEDWATCH WILL BE FILED. DETAILED PRODUCT INFORMATION WAS NOT PROVIDED TO BSC. GOOD FAITH EFFORTS TO OBTAIN THE INFORMATION ARE IN PROGRESS. BECAUSE THE PRODUCT IS UNKNOWN, WE ARE UNABLE TO PROVIDE THE UNIQUE IDENTIFIER (UDI) AND OTHER SPECIFIC PRODUCT INFORMATION AT THIS TIME. A SUPPLEMENTAL REPORT WILL BE FILED IF THE INFORMATION IS RECEIVED.
IT WAS REPORTED THAT A PERICARDIAL EFFUSION (PE) OCCURRED. DURING AN ATRIAL FIBRILLATION ABLATION WITH FARAPULSE PROCEDURE, A FARAWAVE NAV CATHETER AND VERSACROSS CONNECT ACCESS SOLUTION FOR FARADRIVE WERE SELECTED FOR USE. THERE WAS A SMALL TO MODERATE BASELINE EFFUSION NOTED AT THE START OF THE PROCEDURE. THE PHYSICIAN COMPLETED THE PULMONARY VEIN ISOLATION PROCEDURE AND DURING POST MAP, A PRESSURE DROP WAS NOTED. THE EFFUSION WAS CHECKED AND AN INCREASE WAS NOTED. PATIENT'S CHEST WAS THEN TAPPED AND DRAINED 360ML. PATIENT REMAINED STABLE THE ENTIRE TIME AND WAS EXTUBATED AND WOKE UP WITHOUT ISSUES. THE PATIENT WAS ADMITTED FOR OBSERVATION BUT AWAKE AND DOING WELL PER OPERATING PHYSICIAN. IN THE PHYSICIAN OPINION, THE A NON-BOSTON SCIENTIFIC GUIDEWIRE MAY HAVE PERFORATED AN UNKNOWN AREA OF THE LEFT ATRIUM. THE DEVICE IS NOT EXPECTED TO BE RETURNED FOR ANALYSIS (DISPOSED). IT WAS FURTHER REPORTED THAT NO DIFFICULT DURING TRANSSEPTAL WAS NOTED. THE PE WAS LOCATED AROUND RIGHT VENTRICLE (RV), AND A MODERATE BASELINE EFFUSION WAS NOTED IN THIS LOCATION. ACT WAS THERAPEUTIC. THE PATIENT HAS BEEN DISCHARGED.
IT WAS REPORTED THAT A PERICARDIAL EFFUSION (PE) OCCURRED. DURING AN ATRIAL FIBRILLATION ABLATION WITH FARAPULSE PROCEDURE, A FARAWAVE NAV CATHETER AND VERSACROSS CONNECT ACCESS SOLUTION FOR FARADRIVE WERE SELECTED FOR USE. THERE WAS A SMALL TO MODERATE BASELINE EFFUSION NOTED AT THE START OF THE PROCEDURE. THE PHYSICIAN COMPLETED THE PULMONARY VEIN ISOLATION PROCEDURE AND DURING POST MAP, A PRESSURE DROP WAS NOTED. THE EFFUSION WAS CHECKED AND AN INCREASE WAS NOTED. PATIENT'S CHEST WAS THEN TAPPED AND DRAINED 360ML. PATIENT REMAINED STABLE THE ENTIRE TIME AND WAS EXTUBATED AND WOKE UP WITHOUT ISSUES. THE PATIENT WAS ADMITTED FOR OBSERVATION BUT AWAKE AND DOING WELL PER OPERATING PHYSICIAN. IN THE PHYSICIAN OPINION, THE A NON-BOSTON SCIENTIFIC GUIDEWIRE MAY HAVE PERFORATED AN UNKNOWN AREA OF THE LEFT ATRIUM. THE DEVICE IS NOT EXPECTED TO BE RETURNED FOR ANALYSIS (DISPOSED).
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 127231 | VERSACROSS CONNECT ACCESS SOLUTION FOR FARADRIVE | CATHETER, SEPTOSTOMY | DXF | BAYLIS MEDICALE CIE INC |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | NA | Female | Hospitalization| R |